ARTHEx pharma is a spin-off company from the University of Valencia focused on the development of Antisense RNA treatments for genetic diseases. The founders of the company are Dr. Beatriz Llamusí and Dr. Ruben Artero. The first product will be the development of a new drug (small molecule) addressed to the treatment of myotonic dystrophy (DM). DM is the most common muscle dystrophy in adults and it is a highly disabling disease with symptoms involving the skeletal musculature, the heart, and the nervous system. Thus, ARTHEx is a company that aims to develop a treatment against this disease based on microRNA inhibitors.
The business model proposed is based on an open innovation model in which the biotechnology company develops the products until phase 2 (efficacy), and then licenses them to pharmaceutical multinationals with the capacity to complete the development studies more advanced and its commercialization
Location: Spain, l'Horta Oest, Paterna
Employees: 11-50
Total raised: $51.32M
Founded date: 2019
Investors 1
| Date | Name | Website |
| 14.05.2023 | Hadean Ven... | hadeanvent... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.05.2023 | Series B | $46.37M | European I... |
| 24.07.2020 | - | $4.95M | Advent Fra... |
Mentions in press and media 18
| Date | Title | Description | Source |
| 21.12.2023 | Hadean Ventures announces oversubscribed final close of Hade... | Hadean Ventures announces oversubscribed final close of Hadean Capital II – a fund dedicated to inve... | hadeanvent... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia... | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital fl... | fiercebiot... |
| 19.08.2023 | Revolutionizing Biotechnology in Spain: Unveiling 15 Innovat... | Embark on a journey through Spain’s thriving biotechnology landscape, where innovation intersects wi... | eustartup.... |
| 11.05.2023 | Arthex Biotech closes a €42M Series B financing round | EIT Health-supported start-up, Arthex Biotech, has successfully closed a €42 million Series B financ... | eithealth.... |
| 04.05.2023 | ARTHEx Biotech announces Closing of €42M Series B round led ... | 04/05/2023 Nota de prensa ARTHEX BIOTECH ANNOUNCES CLOSING OF €42M SERIES B ROUND LED BY COLUMBUS.... | webcapital... |
| 03.05.2023 | ARTHEx Biotech Announces Closing of €42 M Series B Financing... | ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment ... | hadeanvent... |
| 03.05.2023 | ARTHEx Biotech Closes €42M Series B Financing | ARTHEx Biotech, a Valencia, Spain-based clinical-stage biotechnology company, raised €42M in Series ... | finsmes.co... |
| 10.11.2022 | Three EIT Health Catapult alumni receive EIC grants | A new wave of deep tech start-ups will receive accelerator grants and equity investments from the Eu... | eithealth.... |
| 06.12.2021 | 21 start-ups reach EIT Health Catapult Final | Twenty-one start-ups from across Europe have secured their places at the EIT Health Catapult Final. ... | eithealth.... |
| 22.09.2021 | 21 start-ups selected to innovate for healthy ageing | The awards are part of the Healthy Longevity Global Competition – a multiyear, multimillion-dollar i... | eithealth.... |
Show more